A monthly price buys a vial. What a course of treatment actually involves, on the account of people who study it, is longer than that — and the difference is a recurring cost nobody puts on a pricing page — of a piece with the charges counted in the gap between what is shown and what is billed, except that this one is not even the seller’s to charge.
What the review recommends
A 2025 narrative review sets out dietary supplement considerations during treatment with these drugs [1]. It names multivitamins to address micronutrient insufficiencies; protein supplements to reach a daily intake of 1.2 to 2.0 g per kg; whey protein combined with resistance training to preserve lean mass; creatine monohydrate and HMB for additional strength; antioxidants and anti-inflammatory nutrients for oxidative stress; and fiber and probiotics for bowel regularity and side effects.
The one number worth acting on
The protein target is concrete and checkable: 1.2 to 2.0 g per kilogram per day. For someone weighing 90 kg that is 108 to 180 g daily, which is substantially more than most people eat and considerably harder to reach on an appetite these drugs are designed to suppress.
That is also where the evidence is strongest, because protein with resistance training is the intervention shown to change the lean-mass outcome rather than merely to be recommended. We cost that one out in the cost nobody prices: keeping muscle and quantify the effect in how much of it is muscle, so this page does not repeat either.
Where the rest sits
Fiber and probiotics are recommended for the side effects — the constipation and irregularity that accompany slowed gastric emptying. That is a smaller claim and a cheaper purchase, and it addresses the complaints most likely to make someone stop, which is the commonest way this treatment ends short of anyone deciding anything.
The multivitamin recommendation rests on the plainest mechanism of all: eating substantially less food means taking in less of everything in it. That applies to any effective weight-loss intervention rather than to these drugs in particular.
What it adds to a monthly figure
Nothing published says. Across the 432 injected semaglutide figures recorded here, the median billed rate is $179 a month, read September 2026, and that figure buys the drug. Every item above is bought separately, by the buyer, from someone else, and none of it appears in any seller’s arithmetic.
A reader budgeting a year should price the list they intend to follow alongside the vial. The vial arithmetic is in what a GLP-1 actually costs, and the charges sellers do impose outside their headlines are counted in the gap between what is shown and what is billed.